Pulse Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +127.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -54.0% | Better than 1% |
| Operating margin | -21,982.6% | Better than 0% |
| Net margin | -20,794.6% | Better than 0% |
| Return on equity | -74.4% | Better than 6% |
| Return on invested capital | -72.7% | Better than 4% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -9.7% | Better than 51% |
| 6-month return | 75.9% | Better than 98% |
| 12-month return (ex latest month) | 307.5% | Better than 100% |
| Distance below 52-week high | 22.7% | Better than 55% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.5x | Better than 94% |
| Debt to assets | 8.0% | Better than 73% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 46.4% | Better than 64% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 44.41
- Open
- 44.00
- Day range
- 43.72 - 46.06
- Avg price
- 45.42
- Volume
- 466.85K
- Turnover
- 21.20M
- Turnover ratei
- 2.04%
- Volume ratioi
- 1.01
- Amplitudei
- 5.27%
- 52-week rangei
- 12.95 - 58.94
Valuation
- P/Ei
- -42.18
- P/E (TTM)i
- -37.64
- P/Bi
- 18.25
- EPSi
- -1.08
- Book value / shi
- 2.50
- Net profit
- -79.43M
- Net assets
- 183.58M
Share structure
- Market cap
- 3.35B
- Float capi
- 1.04B
- Shares out
- 73.55M
- Float sharesi
- 22.88M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-05-18
22.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.61M net over the window
Short interest
- Shares short
- 2.90M
- % of floati
- 4.07%
- Days to coveri
- 8.25
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Pulse Biosciences (PLSE)?
Pulse Biosciences last traded at 45.55. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Pulse Biosciences's market cap?
About 3.35B.
What is the P/E ratio of Pulse Biosciences?
The trailing twelve-month P/E is -37.64. The Valuation tab shows it against the stock's own five-year range.
Does Pulse Biosciences pay a dividend?
Pulse Biosciences does not currently pay a regular dividend.
Is Pulse Biosciences a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 66.67, which implies 46.4% upside from the current price. This is not investment advice.
What is Pulse Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Pulse Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Pulse Biosciences discussion 0 comments